TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The study is a prospective, single arm open label study, designed to test the to evaluate the
tolerability and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A
concomitant to Radiotherapy/Temozolomide followed by Temozolomide. The device is a portable,
battery operated device for chronic administration of alternating electric fields (termed
TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated
electrode arrays.